Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

February 9, 2023

Primary Completion Date

January 26, 2024

Study Completion Date

March 23, 2024

Conditions
Asthma
Interventions
DRUG

MG-ZG122 Humanized Monoclonal Antibody Injection

Single subcutaneous injection. Subjects with a dose of less than or equal to 2 ml were given one injection, and subjects with a dose of more than 2 ml were given two injections. A group 0.5 ml, B group 1 ml, C group 2 ml, D group 4 ml.

DRUG

Placebo

Single subcutaneous injection. Subjects with a dose of less than or equal to 2 ml were given one injection, and subjects with a dose of more than 2 ml were given two injections. A group 0.5 ml, B group 1 ml, C group 2 ml, D group 4 ml.

Trial Locations (1)

230601

The Second Affiliated Hospital of Anhui Medical University, Hefei

All Listed Sponsors
lead

Shanghai Mabgeek Biotech.Co.Ltd

OTHER_GOV